The Swiss pharmaceutical company Roche reported that in the third quarter, it managed to increase sales by 7% to 13 billion 970 million Swiss francs due to an increase in revenue from the sale of new drugs, finversia.ru wrote. The indicator exceeded the forecasts of experts who had expected sales of 13,800 million francs. The company doubled its quarterly revenue from sales of Ocrevus, the drug for multiple sclerosis, compared to last year, and by 62% from sales of the anti-cancer drug Alecensa. Sales of another two new drugs – Perjeta, for the treatment of breast cancer, and the immunological drug Tecentriq – increased in annual terms by 27% and 71%, respectively.
On Friday, Caterpillar Inc (CAT.N) announced a lower second-quarter profit because of the recession caused by the coronavirus outbreak. The decline was due to lower sales volume and changes in dealer inventories. During the second quarter ...
On Thursday, the United States’ Gross Domestic Product (GDP) suffered the biggest economic decline in the second quarter as the surge of coronavirus cases affected the whole country. The U.S. government decided to shut down restaurants, ...
Samsung Electronics Co Ltd looks forward to the second half of the year as it expects a larger increase in chip demand brought by new smartphone launches. However, the company warned that the coronavirus crisis and trade disputes carry risks. Samsung, ...
The second quarter had seen Australian consumer prices dropping by a record. This could be attributed to the coronavirus crisis dragging child care cost and petroleum prices, inflicting a serious damage to years of growth toward higher inflation. Last ...
Spain’s unemployment rose to 15.33% for the second quarter of 2020, according to Tuesday’s data from the National Statistics Institute amid the worsening COVID-19 situation in the country. The unemployment rate surged past the ...